Further studies should be undertaken to better understand this aspect, while the main conclusion of our current work is that we have identified a novel and quite robust new target for therapy in ADPKD, the enzyme ASNS. The gene discussed is ASNS; the disease is autosomal dominant polycystic kidney disease.